Blood
Audio Summaries

Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms

Jun 25, 2026

This study investigates the role of galectin-1 (Gal-1) in driving monocyte hyperinflammation in myeloproliferative neoplasms (MPNs). The authors demonstrate that elevated Gal-1 levels in MPN monocytes enhance inflammatory cytokine production through TLR4 and NF-κB signaling pathways, suggesting that targeting Gal-1 could represent a novel therapeutic strategy for managing MPN-related inflammation.

NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab

Jun 25, 2026

The authors investigate the role of the NG2-ITGA4 signaling axis in the aggressiveness of KMT2A-rearranged B-cell acute lymphoblastic leukemia (KMT2A-r B-ALL), a subtype associated with poor prognosis and high relapse rates. They demonstrate that NG2 promotes cell proliferation and migration through Rho GTPase activity in an ITGA4-dependent manner, and show that targeting ITGA4 with natalizumab can delay leukemia progression and enhance chemotherapy efficacy in patient-derived models. This study highlights a potential therapeutic strategy for improving outcomes in KMT2A-r B-ALL patients.

Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate

Jun 25, 2026

The authors investigate how mRNA isoform regulation influences the fate decisions of hematopoietic stem cells (HSCs) during their transition from quiescence to lineage commitment. They identify the splicing regulator Sf1 as a critical component of a translationally controlled splicing program that modulates HSC differentiation and DNA damage response through alternative splicing. This study highlights the intricate relationship between translational regulation, splicing, and HSC fate determination.

Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial

Jun 25, 2026

The study aimed to evaluate the efficacy of adding the tyrosine kinase inhibitor Quizartinib to intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS), regardless of FLT3 mutation status. While Quizartinib did not improve overall survival for the entire cohort, it significantly enhanced survival in FLT3-mutated patients, particularly those receiving a shorter duration of treatment. The findings suggest that Quizartinib may be beneficial for specific subgroups, highlighting the importance of genetic profiling in treatment strategies.

Direct and indirect regulation of fetal globin transcript by RNA-binding protein IGF2BP1

Jun 24, 2026

The authors investigate the role of the RNA-binding protein IGF2BP1 in the regulation of fetal globin transcripts, specifically HBG1/2, and its relationship with the transcriptional repressor BCL11A. They reveal that IGF2BP1 not only indirectly regulates HBG1/2 by suppressing BCL11A but also directly binds to HBG1/2 transcripts to enhance their translation through m6A modifications. This study enhances the understanding of the molecular mechanisms underlying hemoglobin switching during development.

Niche-targeted therapy via YAP/TAZ activation enhances hematopoietic regeneration

Jun 22, 2026

The authors investigate the role of YAP/TAZ activation in enhancing hematopoietic regeneration following myeloablative stress, focusing on how these pathways can restore the bone marrow niche that supports hematopoietic stem cells (HSCs). They demonstrate that YAP/TAZ are crucial for the recovery of endothelial cells and mesenchymal stromal cells, which in turn promotes efficient hematopoietic recovery. The study suggests that pharmacological activation of YAP/TAZ could serve as a therapeutic strategy to improve hematopoietic regeneration by enhancing niche resilience.

Retinoic acid-driven expansion of CD16hiCD177+ neutrophils mediates steroid-resistant GI-GVHD

Jun 20, 2026

The authors investigate the role of a specific neutrophil subset (CD16hiCD177⁺) in the pathogenesis of steroid-resistant gastrointestinal graft-versus-host disease (SR-GI-GVHD) following allogeneic hematopoietic stem cell transplantation. They find that elevated retinoic acid levels drive the expansion and pathogenic programming of these neutrophils, which contribute to tissue damage through the release of neutrophil extracellular traps. The study suggests that targeting the retinoic acid receptor may offer a novel therapeutic approach to improve treatment outcomes for SR-GI-GVHD.

Expanded antigen-specific donor regulatory T cells for GVHD prevention

Jun 20, 2026

The authors aimed to evaluate the safety and preliminary efficacy of expanding and infusing minor histocompatibility antigen (mHAg)-specific donor regulatory T cells (Treg) for preventing graft vs. host disease (GVHD) in allogeneic hematopoietic cell transplantation. In a phase I trial involving 15 subjects, they found no dose-limiting toxicities and identified a maximum tolerated dose of 4 x 10^5/kg Treg, with low incidences of acute and chronic GVHD and a 73% overall survival rate at a median follow-up of 41.7 months. The study supports the potential of mHAg-specific expanded donor Treg as a novel strategy for GVHD prevention.

Aberrant splicing of MBD1 reshapes the epigenome to drive convergent myeloerythroid defects in MDS

Jun 20, 2026

The authors investigate the role of a novel MBD1 isoform (MBD1-L) in myelodysplastic neoplasms (MDS) and its impact on hematopoietic function, particularly in the context of splicing abnormalities independent of specific mutations. They find that MBD1-L, driven by reduced WTAP expression, leads to significant myeloerythroid defects by altering MBD1's binding behavior and epigenetic regulation, and they demonstrate that reversing this aberrant splicing can enhance erythroid differentiation in MDS samples, highlighting the potential for RNA-based therapies.

Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial

Jun 20, 2026

The authors aimed to investigate the impact of genetic risk factors on treatment outcomes for early-stage chronic lymphocytic leukemia (CLL) patients receiving ibrutinib versus placebo in the GCLLSG CLL12 trial. They found that while ibrutinib improved event-free survival (EFS) in certain genetic subgroups, such as those with U-IGHV and del(11q) mutations, it did not provide overall survival (OS) benefits across any genetic subgroup, reinforcing the watch-and-wait strategy for asymptomatic early-stage CLL patients, particularly those with del(17p) or TP53 mutations.